Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Liu J, et al. Among authors: zeng x. Ann Rheum Dis. 2024 Nov 27:ard-2024-226385. doi: 10.1136/ard-2024-226385. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39603709
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X; Chinese Registry of Rheumatoid Arthritis co-authors. Xiang Y, et al. Among authors: zeng x. Int J Rheum Dis. 2020 Dec;23(12):1719-1727. doi: 10.1111/1756-185X.13996. Epub 2020 Oct 9. Int J Rheum Dis. 2020. PMID: 33034424
Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
Yu C, Li M, Duan X, Fang Y, Li Q, Wu R, Liu S, Wang Y, Wu Z, Shi X, Jiang Z, Wang Y, Hsieh ED, Jin S, Jiang N, Wang Q, Zhao Y, Tian X, Zeng X; and the co-authors of CREDIT. Yu C, et al. Among authors: zeng x. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):836-840. Epub 2018 Mar 21. Clin Exp Rheumatol. 2018. PMID: 29600939 Free article.
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations.
Jin S, Jiang N, Huo Y, Duan X, Fang Y, Zhao C, Li H, Yang M, Huang Z, Yang P, Zhang H, Zhan F, Wang Y, Wang Y, Wu C, Wang Q, Hsieh E, Li M, Tian X, Zhao Y, Zeng X. Jin S, et al. Among authors: zeng x. Ann Rheum Dis. 2022 Jul;81(7):1052-1054. doi: 10.1136/annrheumdis-2021-221841. Epub 2022 Feb 15. Ann Rheum Dis. 2022. PMID: 35168947 No abstract available.
Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, Jiang Z, Wang Y, Yu C, Wang Q, Tian X, Zhao Y, Zeng X; CREDIT Co-authors. Jin S, et al. Among authors: zeng x. Arthritis Res Ther. 2017 Nov 15;19(1):251. doi: 10.1186/s13075-017-1457-z. Arthritis Res Ther. 2017. PMID: 29141688 Free PMC article.
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Leng X, Leszczyński P, Jeka S, Liu SY, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Rezk M, Mitroiu M, Addison J, Zeng X. Leng X, et al. Among authors: zeng x. Lancet Rheumatol. 2024 Jan;6(1):e40-e50. doi: 10.1016/S2665-9913(23)00237-0. Lancet Rheumatol. 2024. PMID: 38258678 Clinical Trial.
15,313 results
You have reached the last available page of results. Please see the User Guide for more information.